CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome

Sponsor

Chonnam National University Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT00991679

Collaborator

(none)

Enrollment

Location

Duration (Months)

4.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is to investigate the expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.

Thirty-three patients with dry eye (16 Sjögren's syndrome and 17 non-Sjögren's syndrome patients) and 15 control subjects were recruited. The concentrations of CXCL9, CXCL10, and CXCL11 in tears were measured using enzyme-linked immunosorbent assay. The correlation between chemokine levels and tear film and ocular surface parameters was analyzed. Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the conjunctiva was evaluated using immunohistochemistry. Flow cytometry was performed to count CXCR3+ cells and CXCR3+CD4+ cells in the conjunctiva.

Condition or Disease	Intervention/Treatment	Phase
Dry Eye Syndrome

Study Design

Study Type:

Observational

Actual Enrollment :

48 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the Tear Film and Ocular Surface of Patients With Dry Eye Syndrome

Study Start Date :

Feb 1, 2008

Actual Primary Completion Date :

Oct 1, 2008

Actual Study Completion Date :

Dec 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Normal control subjects Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
dry eye patients Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.